Skip to main content
SpringerLink
Log in

Update on the Role of Colchicine in Cardiovascular Disease

  • Ischemic Heart Disease (D Mukherjee, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review focuses on the use of colchicine to target inflammation to prevent cardiovascular events among those at-risk for or with established coronary artery disease.

Recent Findings

Colchicine is an anti-inflammatory drug that reduces cardiovascular events through its effect on the IL-1β/IL-6/CRP pathway, which promotes the progression and rupture of atherosclerotic plaques. Clinical trials have demonstrated that colchicine reduces cardiovascular events by 31% among those with chronic coronary disease, and by 23% among those with recent myocardial infarction. Its ability to dampen inflammation during an acute injury may broaden its scope of use in patients at risk for cardiovascular events after major non-cardiac surgery.

Summary

Colchicine is an effective anti-inflammatory therapy in the prevention of acute coronary syndrome. Ongoing studies aim to assess when, and in whom, colchicine is most effective to prevent cardiovascular events in patients at-risk for or with established coronary artery disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data Availability

No datasets were generated or analysed during the current study.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002;106(23):2894–900. https://doi.org/10.1161/01.cir.0000042674.89762.20.

    Article  PubMed  Google Scholar 

  2. Quillard T, Araújo HA, Franck G, Shvartz E, Sukhova G, Libby P. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: Implications for superficial erosion. Eur Heart J. 2015;36(22):1394–404. https://doi.org/10.1093/eurheartj/ehv044.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31. https://doi.org/10.1056/NEJMoa1707914.

    Article  CAS  PubMed  Google Scholar 

  4. Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: A collaborative analysis of three randomised trials. Lancet. 2023;401(10384):1293–301. https://doi.org/10.1016/s0140-6736(23)00215-5.

    Article  CAS  PubMed  Google Scholar 

  5. •• Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752–62. https://doi.org/10.1056/NEJMoa1809798. The CANTOS randomized control trial demonstrated that the IL-1B inhibitor canakinumab reduced cardiovascular events among those with AMI and elevated hs-CRP with a concurrent increase in fatal infections.

    Article  CAS  PubMed  Google Scholar 

  6. Crittenden DB, Lehmann RA, Schneck L, Keenan RT, Shah B, Greenberg JD, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39(7):1458–64. https://doi.org/10.3899/jrheum.111533.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Solomon DH, Liu CC, Kuo IH, Zak A, Kim SC. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: A cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016;75(9):1674–9. https://doi.org/10.1136/annrheumdis-2015-207984.

    Article  CAS  PubMed  Google Scholar 

  8. •• Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–505. https://doi.org/10.1056/NEJMoa1912388. The COLCOT randomized control trial demonstrated that colchicine reduced cardiovascular events by 23% among those with recent AMI.

    Article  CAS  PubMed  Google Scholar 

  9. •• Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–47. https://doi.org/10.1056/NEJMoa2021372. LoDoCo-2 randomized control trial showed that colchicine reduced cardiovascular events by 31% among those with chronic coronary disease.

    Article  CAS  PubMed  Google Scholar 

  10. Shah B, Toprover M, Crittenden DB, Jeurling S, Pike VC, Krasnokutsky S, et al. Colchicine use and incident coronary artery disease in male patients with gout. Can J Cardiol. 2020;36(11):1722–8. https://doi.org/10.1016/j.cjca.2020.05.026.

    Article  PubMed  Google Scholar 

  11. Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation. 2011;123(6):594–604. https://doi.org/10.1161/circulationaha.110.982777.

    Article  CAS  PubMed  Google Scholar 

  12. Shah B, Baber U, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, et al. White blood cell count and major adverse cardiovascular events after percutaneous coronary intervention in the contemporary era: Insights from the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circ Cardiovasc Interv. 2017;10(9). https://doi.org/10.1161/circinterventions.117.004981.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: A secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319–28. https://doi.org/10.1016/s0140-6736(17)32814-3.

    Article  CAS  PubMed  Google Scholar 

  14. Martínez GJ, Robertson S, Barraclough J, Xia Q, Mallat Z, Bursill C, et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc. 2015;4(8):e002128. https://doi.org/10.1161/jaha.115.002128.

    Article  PubMed  PubMed Central  Google Scholar 

  15. • Shah B, Pillinger M, Zhong H, Cronstein B, Xia Y, Lorin JD, et al. Effects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI randomized trial. Circ Cardiovasc Interv. 2020;13(4):e008717. https://doi.org/10.1161/circinterventions.119.008717. This randomized control trial demonstrated for the first time that colchicine can dampen the inflammatory response to acute injury.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Toprover M, Shah B, Oh C, Igel TF, Romero AG, Pike VC, et al. Initiating guideline-concordant gout treatment improves arterial endothelial function and reduces intercritical inflammation: A prospective observational study. Arthritis Res Ther. 2020;22(1):169. https://doi.org/10.1186/s13075-020-02260-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Fujisue K, Sugamura K, Kurokawa H, Matsubara J, Ishii M, Izumiya Y, et al. Colchicine improves survival, left ventricular remodeling, and chronic cardiac function after acute myocardial infarction. Circ J. 2017;81(8):1174–82. https://doi.org/10.1253/circj.CJ-16-0949.

    Article  CAS  PubMed  Google Scholar 

  18. Bakhta O, Blanchard S, Guihot AL, Tamareille S, Mirebeau-Prunier D, Jeannin P, et al. Cardioprotective role of colchicine against inflammatory injury in a rat model of acute myocardial infarction. J Cardiovasc Pharmacol Ther. 2018;23(5):446–55. https://doi.org/10.1177/1074248418763611.

    Article  CAS  PubMed  Google Scholar 

  19. Forrat R, Sebbag L, Ferrera R, Hadour G, Canet E, Tabib A, et al. Effect of colchicine on circulating and myocardial neutrophils and on infarct size in a canine model of ischemia and reperfusion. J Cardiovasc Pharmacol. 1996;27(6):876–83. https://doi.org/10.1097/00005344-199606000-00016.

    Article  CAS  PubMed  Google Scholar 

  20. Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest. 1995;96(2):994–1002. https://doi.org/10.1172/jci118147.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Yang M, Lv H, Liu Q, Zhang L, Zhang R, Huang X, et al. Colchicine Alleviates cholesterol crystal-induced endothelial cell pyroptosis through activating AMPK/SIRT1 pathway. Oxid Med Cell Longev. 2020;2020:9173530. https://doi.org/10.1155/2020/9173530.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Meyer-Lindemann U, Mauersberger C, Schmidt AC, Moggio A, Hinterdobler J, Li X, et al. Colchicine impacts leukocyte trafficking in atherosclerosis and reduces vascular inflammation. Front Immunol. 2022;13:898690. https://doi.org/10.3389/fimmu.2022.898690.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kiraz S, Ertenli I, Arici M, Calgüneri M, Haznedaroglu I, Celik I, et al. Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever. Clin Exp Rheumatol. 1998;16(6):721–4.

    CAS  PubMed  Google Scholar 

  24. Bauriedel G, Heimerl J, Beinert T, Welsch U, Höfling B. Colchicine antagonizes the activity of human smooth muscle cells cultivated from arteriosclerotic lesions after atherectomy. Coron Artery Dis. 1994;5(6):531–9.

    CAS  PubMed  Google Scholar 

  25. Abu-Fanne R, Stepanova V, Litvinov RI, Abdeen S, Bdeir K, Higazi M, et al. Neutrophil α-defensins promote thrombosis in vivo by altering fibrin formation, structure, and stability. Blood. 2019;133(5):481–93. https://doi.org/10.1182/blood-2018-07-861237.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Mori H, Taki J, Wakabayashi H, Hiromasa T, Inaki A, Ogawa K, et al. Colchicine treatment early after infarction attenuates myocardial inflammatory response demonstrated by (14)C-methionine imaging and subsequent ventricular remodeling by quantitative gated SPECT. Ann Nucl Med. 2021;35(2):253–9. https://doi.org/10.1007/s12149-020-01559-3.

    Article  CAS  PubMed  Google Scholar 

  27. Aimo A, Martinez-Falguera D, Barison A, Musetti V, Masotti S, Morfino P, et al. Colchicine added to standard therapy further reduces fibrosis in pigs with myocardial infarction. J Cardiovasc Med (Hagerstown). 2023;24(11):840–6. https://doi.org/10.2459/jcm.0000000000001554.

    Article  CAS  PubMed  Google Scholar 

  28. Schwarz N, Fernando S, Chen YC, Salagaras T, Rao SR, Liyanage S, et al. Colchicine exerts anti-atherosclerotic and -plaque-stabilizing effects targeting foam cell formation. Faseb J. 2023;37(4):e22846. https://doi.org/10.1096/fj.202201469R.

    Article  CAS  PubMed  Google Scholar 

  29. Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol. 2007;99(6):805–7. https://doi.org/10.1016/j.amjcard.2006.10.039.

    Article  CAS  PubMed  Google Scholar 

  30. Shah B, Allen N, Harchandani B, Pillinger M, Katz S, Sedlis SP, et al. Effect of colchicine on platelet-platelet and platelet-leukocyte interactions: A pilot study in healthy subjects. Inflammation. 2016;39(1):182–9. https://doi.org/10.1007/s10753-015-0237-7.

    Article  CAS  PubMed  Google Scholar 

  31. •• Vaidya K, Arnott C, Martínez GJ, Ng B, McCormack S, Sullivan DR, et al. Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: A CT coronary angiography study. JACC Cardiovasc Imaging. 2018;11(2 Pt 2):305–16. https://doi.org/10.1016/j.jcmg.2017.08.013. This observational trial showed that colchicine reduced low-attenuation plaque burden on coronary CT and reduced hs-CRP at one year among those with recent AMI.

    Article  PubMed  Google Scholar 

  32. Langevitz P, Livneh A, Neumann L, Buskila D, Shemer J, Amolsky D, et al. Prevalence of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J. 2001;3(1):9–12.

    CAS  PubMed  Google Scholar 

  33. •• Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–10. https://doi.org/10.1016/j.jacc.2012.10.027. LoDoCo showed that colchicine reduced the rate of cardiovascular events, driven by reduction in AMI, with a number-needed-to-treat of 11 patients.

    Article  CAS  PubMed  Google Scholar 

  34. Opstal TSJ, Fiolet ATL, van Broekhoven A, Mosterd A, Eikelboom JW, Nidorf SM, et al. Colchicine in patients with chronic coronary disease in relation to prior acute coronary syndrome. J Am Coll Cardiol. 2021;78(9):859–66. https://doi.org/10.1016/j.jacc.2021.06.037.

    Article  PubMed  Google Scholar 

  35. Silvis MJM, Fiolet ATL, Opstal TSJ, Dekker M, Suquilanda D, Zivkovic M, et al. Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: A LoDoCo2 biomarker substudy. Atherosclerosis. 2021;334:93–100. https://doi.org/10.1016/j.atherosclerosis.2021.08.005.

    Article  CAS  PubMed  Google Scholar 

  36. Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos N, Filippatos G, Papoutsidakis N, et al. Anti-inflammatory treatment with colchicine in acute myocardial infarction: A pilot study. Circulation. 2015;132(15):1395–403. https://doi.org/10.1161/circulationaha.115.017611.

    Article  CAS  PubMed  Google Scholar 

  37. •• Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, et al. Colchicine in patients with acute coronary syndrome: The Australian COPS randomized clinical trial. Circulation. 2020;142(20):1890–900. https://doi.org/10.1161/circulationaha.120.050771.The COPS randomized control trial did not demonstrate a reduction in cardiovascular events at one year when colchicine was administered to those with recent AMI but did show a previously unobserved increase in non-cardiovascular deaths.

    Article  PubMed  Google Scholar 

  38. •• Tong DC, Bloom JE, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, et al. Colchicine in patients with acute coronary syndrome: Two-year follow-up of the Australian COPS randomized clinical trial. Circulation. 2021;144(19):1584–6. https://doi.org/10.1161/circulationaha.121.054610. This two year follow up of the COPS trial showed that colchicine reduced cardiovascular events among those with recent AMI.

    Article  PubMed  Google Scholar 

  39. Bouabdallaoui N, Tardif JC, Waters DD, Pinto FJ, Maggioni AP, Diaz R, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J. 2020;41(42):4092–9. https://doi.org/10.1093/eurheartj/ehaa659.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364(3):226–35. https://doi.org/10.1056/NEJMoa1002358.

    Article  CAS  PubMed  Google Scholar 

  41. O’Keefe JH Jr, McCallister BD, Bateman TM, Kuhnlein DL, Ligon RW, Hartzler GO. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol. 1992;19(7):1597–600. https://doi.org/10.1016/0735-1097(92)90624-v.

    Article  PubMed  Google Scholar 

  42. Rab ST, King SB 3rd, Roubin GS, Carlin S, Hearn JA, Douglas JS Jr. Coronary aneurysms after stent placement: A suggestion of altered vessel wall healing in the presence of anti-inflammatory agents. J Am Coll Cardiol. 1991;18(6):1524–8. https://doi.org/10.1016/0735-1097(91)90685-3.

    Article  CAS  PubMed  Google Scholar 

  43. Freed M, Safian RD, O’Neill WW, Safian M, Jones D, Grines CL. Combination of lovastatin, enalapril, and colchicine does not prevent restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1995;76(16):1185–8. https://doi.org/10.1016/s0002-9149(99)80334-8.

    Article  CAS  PubMed  Google Scholar 

  44. Deftereos S, Giannopoulos G, Raisakis K, Kossyvakis C, Kaoukis A, Panagopoulou V, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol. 2013;61(16):1679–85. https://doi.org/10.1016/j.jacc.2013.01.055.

    Article  CAS  PubMed  Google Scholar 

  45. Vaidya K, Tucker B, Kurup R, Khandkar C, Pandzic E, Barraclough J, et al. Colchicine inhibits neutrophil extracellular trap formation in patients with acute coronary syndrome after percutaneous coronary intervention. J Am Heart Assoc. 2021;10(1):e018993. https://doi.org/10.1161/jaha.120.018993.

    Article  CAS  PubMed  Google Scholar 

  46. Shah B, Smilowitz NR, Xia Y, Feit F, Katz SD, Zhong J, et al. Major adverse cardiovascular events after colchicine administration before percutaneous coronary intervention: Follow-up of the colchicine-PCI trial. Am J Cardiol. 2023;204:26–8. https://doi.org/10.1016/j.amjcard.2023.07.029.

    Article  CAS  PubMed  Google Scholar 

  47. •• Cole J, Htun N, Lew R, Freilich M, Quinn S, Layland J. Colchicine to prevent periprocedural myocardial injury in percutaneous coronary intervention: The COPE-PCI pilot trial. Circ Cardiovasc Interv. 2021;14(5):e009992. https://doi.org/10.1161/circinterventions.120.009992. This randomized control pilot trial showed that colchicine administered peri-procedurally among those undergoing percutaneous coronary intervention reduced the incidence of myocardial injury when given 6-24 hours in advance.

    Article  CAS  PubMed  Google Scholar 

  48. Samuel M, Tardif JC, Bouabdallaoui N, Khairy P, Dubé MP, Blondeau L, et al. Colchicine for secondary prevention of cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials. Can J Cardiol. 2021;37(5):776–85. https://doi.org/10.1016/j.cjca.2020.10.006.

    Article  PubMed  Google Scholar 

  49. Kofler T, Kurmann R, Lehnick D, Cioffi GM, Chandran S, Attinger-Toller A, et al. Colchicine in patients with coronary artery disease: A systematic review and meta-analysis of randomized trials. J Am Heart Assoc. 2021;10(16):e021198. https://doi.org/10.1161/jaha.121.021198.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Fiolet ATL, Opstal TSJ, Mosterd A, Eikelboom JW, Jolly SS, Keech AC, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: A systematic review and meta-analysis of randomized trials. Eur Heart J. 2021;42(28):2765–75. https://doi.org/10.1093/eurheartj/ehab115.

    Article  CAS  PubMed  Google Scholar 

  51. Robinson PC, Terkeltaub R, Pillinger MH, Shah B, Karalis V, Karatza E, et al. Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease. Am J Med. 2022;135(1):32–8. https://doi.org/10.1016/j.amjmed.2021.07.025.

    Article  CAS  PubMed  Google Scholar 

  52. Samuel M, Tardif JC, Khairy P, Roubille F, Waters DD, Grégoire JC, et al. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J Qual Care Clin Outcomes. 2021;7(5):486–95. https://doi.org/10.1093/ehjqcco/qcaa045.

    Article  PubMed  Google Scholar 

  53. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060–8. https://doi.org/10.1002/art.27327.

    Article  CAS  PubMed  Google Scholar 

  54. McCormick N, Wallace ZS, Yokose C, Jorge A, Sacks CA, Hsu J, et al. Prolonged increases in public-payer spending and prices after unapproved drug initiative approval of colchicine. JAMA Intern Med. 2021;181(2):284–7. https://doi.org/10.1001/jamainternmed.2020.5017.

    Article  CAS  PubMed  Google Scholar 

  55. Lee SY, Jeong YH, Yun KH, Cho JY, Gorog DA, Angiolillo DJ, et al. P2Y(12) Inhibitor monotherapy combined with colchicine following PCI in ACS patients: The MACT Pilot Study. JACC Cardiovasc Interv. 2023;16(15):1845–55. https://doi.org/10.1016/j.jcin.2023.05.035.

    Article  PubMed  Google Scholar 

  56. Dubé MP, Legault MA, Lemaçon A, Lemieux Perreault LP, Fouodjio R, Waters DD, et al. Pharmacogenomics of the efficacy and safety of colchicine in COLCOT. Circ Genom Precis Med. 2021;14(2):e003183. https://doi.org/10.1161/circgen.120.003183.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leon H Charney Division of Cardiology, NYU Grossman School of Medicine, New York, NY, 10016, USA

    Darcy Banco, Mohammad Mustehsan & Binita Shah

  2. VA New York Harbor Healthcare System, 423 E 23rd Street, Office 12023-W, New York, NY, 10010, USA

    Binita Shah

Authors
  1. Darcy Banco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammad Mustehsan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Binita Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DB and MM conducted literature review and wrote the main manuscript BS developed manuscript outline, assisted with literature review, and edited and reviewed the final manuscript.

Corresponding author

Correspondence to Binita Shah.

Ethics declarations

Conflict of Interest

Dr. Banco and Dr. Mustehsan have nothing to disclose. Dr. Shah receives funding outside this paper—from the NIH and from the VA Office of Research and Development for the CLEAR-SYNERGY biospecimen substudy and POPCORN trials, respectively; serves on the steering committee for the NovoNordisk-funded ARTEMIS trial, CIHR-funded CLEAR SYNERGY Trial, and the Philips Volcano-funded IMPROVE Trial; serves as an advisory board member for Philips Volcano; and serves as a Board of Trustee for the Society of Cardiovascular Angiography and Interventions.

Human and Animal Rights and Informed Consent

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Banco, D., Mustehsan, M. & Shah, B. Update on the Role of Colchicine in Cardiovascular Disease. Curr Cardiol Rep 26, 191–198 (2024). https://doi.org/10.1007/s11886-024-02026-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-024-02026-5

Keywords

Search

Navigation